AR122496A1 - Métodos para preparar vesículas extracelulares y usos de estas - Google Patents

Métodos para preparar vesículas extracelulares y usos de estas

Info

Publication number
AR122496A1
AR122496A1 ARP210101487A ARP210101487A AR122496A1 AR 122496 A1 AR122496 A1 AR 122496A1 AR P210101487 A ARP210101487 A AR P210101487A AR P210101487 A ARP210101487 A AR P210101487A AR 122496 A1 AR122496 A1 AR 122496A1
Authority
AR
Argentina
Prior art keywords
antibody
heterologous protein
cell
evs
animal
Prior art date
Application number
ARP210101487A
Other languages
English (en)
Spanish (es)
Inventor
James Thomas Koerber
Yonglian Sun
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of AR122496A1 publication Critical patent/AR122496A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/531—Production of immunochemical test materials
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—RNA viruses
    • C07K16/112—Retroviridae (F), e.g. leukemia viruses
    • C07K16/114—Lentivirus (G), e.g. human immunodeficiency virus [HIV], feline immunodeficiency virus [FIV] or simian immunodeficiency virus [SIV]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • C12N5/12—Fused cells, e.g. hybridomas
    • C12N5/16—Animal cells
    • C12N5/163—Animal cells one of the fusion partners being a B or a T lymphocyte
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5076—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving cell organelles, e.g. Golgi complex, endoplasmic reticulum
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/566—Immunoassay; Biospecific binding assay; Materials therefor using specific carrier or receptor proteins as ligand binding reagents where possible specific carrier or receptor proteins are classified with their target compounds
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/60—Fusion polypeptide containing spectroscopic/fluorescent detection, e.g. green fluorescent protein [GFP]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Genetics & Genomics (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Toxicology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Virology (AREA)
  • General Engineering & Computer Science (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • AIDS & HIV (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating, Analyzing Materials By Fluorescence Or Luminescence (AREA)
ARP210101487A 2020-06-01 2021-06-01 Métodos para preparar vesículas extracelulares y usos de estas AR122496A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US202063033014P 2020-06-01 2020-06-01

Publications (1)

Publication Number Publication Date
AR122496A1 true AR122496A1 (es) 2022-09-14

Family

ID=76943084

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP210101487A AR122496A1 (es) 2020-06-01 2021-06-01 Métodos para preparar vesículas extracelulares y usos de estas

Country Status (13)

Country Link
US (1) US20230090177A1 (cg-RX-API-DMAC7.html)
EP (1) EP4157866A2 (cg-RX-API-DMAC7.html)
JP (2) JP2023530600A (cg-RX-API-DMAC7.html)
KR (1) KR20230017822A (cg-RX-API-DMAC7.html)
CN (1) CN115667294A (cg-RX-API-DMAC7.html)
AR (1) AR122496A1 (cg-RX-API-DMAC7.html)
AU (1) AU2021285802A1 (cg-RX-API-DMAC7.html)
BR (1) BR112022024472A2 (cg-RX-API-DMAC7.html)
CA (1) CA3182473A1 (cg-RX-API-DMAC7.html)
IL (1) IL298599A (cg-RX-API-DMAC7.html)
MX (1) MX2022014892A (cg-RX-API-DMAC7.html)
TW (2) TWI885439B (cg-RX-API-DMAC7.html)
WO (1) WO2021247457A2 (cg-RX-API-DMAC7.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20242350A1 (es) 2022-05-03 2024-12-16 Genentech Inc Anticuerpos anti-ly6e, inmunoconjugados y usos de estos
CN115845083B (zh) * 2022-12-12 2025-04-11 南京逸微健华生物科技有限公司 一种靶向改造Expi293细胞外泌体递送siMMP13的方法
CN116103293A (zh) * 2022-12-12 2023-05-12 南京逸微健华生物科技有限公司 一种靶向改造Expi293细胞外泌体递送ASO-MMP13的方法

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE337223B (cg-RX-API-DMAC7.html) 1967-05-23 1971-08-02 Pharmacia Ab
US3720760A (en) 1968-09-06 1973-03-13 Pharmacia Ab Method for determining the presence of reagin-immunoglobulins(reagin-ig)directed against certain allergens,in aqueous samples
US3691016A (en) 1970-04-17 1972-09-12 Monsanto Co Process for the preparation of insoluble enzymes
CA1023287A (en) 1972-12-08 1977-12-27 Boehringer Mannheim G.M.B.H. Process for the preparation of carrier-bound proteins
US4195128A (en) 1976-05-03 1980-03-25 Bayer Aktiengesellschaft Polymeric carrier bound ligands
US4330440A (en) 1977-02-08 1982-05-18 Development Finance Corporation Of New Zealand Activated matrix and method of activation
CA1093991A (en) 1977-02-17 1981-01-20 Hideo Hirohara Enzyme immobilization with pullulan gel
US4229537A (en) 1978-02-09 1980-10-21 New York University Preparation of trichloro-s-triazine activated supports for coupling ligands
US4376110A (en) 1980-08-04 1983-03-08 Hybritech, Incorporated Immunometric assays using monoclonal antibodies
US4737456A (en) 1985-05-09 1988-04-12 Syntex (U.S.A.) Inc. Reducing interference in ligand-receptor binding assays
US5241053A (en) * 1990-09-05 1993-08-31 Takeda Chemical Industries, Ltd. Fused proteins comprising glycoprotein gD of HSV-1 and LTB
IE922437A1 (en) 1991-07-25 1993-01-27 Idec Pharma Corp Recombinant antibodies for human therapy
US6267958B1 (en) 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
US6171586B1 (en) 1997-06-13 2001-01-09 Genentech, Inc. Antibody formulation
WO2004073319A2 (en) * 2003-02-14 2004-08-26 Anosys, Inc. Methods and compounds for raising antibodies and for screening antibody repertoires
US20060104968A1 (en) 2003-03-05 2006-05-18 Halozyme, Inc. Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminogly ycanases
US7871607B2 (en) 2003-03-05 2011-01-18 Halozyme, Inc. Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminoglycanases
JO3000B1 (ar) 2004-10-20 2016-09-05 Genentech Inc مركبات أجسام مضادة .
US9737480B2 (en) * 2012-02-06 2017-08-22 President And Fellows Of Harvard College ARRDC1-mediated microvesicles (ARMMs) and uses thereof
US20190112351A1 (en) * 2016-04-04 2019-04-18 National Institutes Of Biomedical Innovation, Health And Nutrition Exosome-targeted dna vaccine
JP2019017341A (ja) * 2017-07-20 2019-02-07 国立研究開発法人国立がん研究センター 標識小胞及びその製造方法

Also Published As

Publication number Publication date
MX2022014892A (es) 2023-01-04
TWI814008B (zh) 2023-09-01
TWI885439B (zh) 2025-06-01
TW202204414A (zh) 2022-02-01
JP2026027260A (ja) 2026-02-18
JP2023530600A (ja) 2023-07-19
CN115667294A (zh) 2023-01-31
CA3182473A1 (en) 2021-12-09
IL298599A (en) 2023-01-01
TW202423962A (zh) 2024-06-16
WO2021247457A3 (en) 2022-01-13
BR112022024472A2 (pt) 2022-12-27
EP4157866A2 (en) 2023-04-05
WO2021247457A2 (en) 2021-12-09
AU2021285802A1 (en) 2022-12-08
KR20230017822A (ko) 2023-02-06
US20230090177A1 (en) 2023-03-23

Similar Documents

Publication Publication Date Title
US20240207334A1 (en) Oncolytic viral delivery of therapeutic polypeptides
JP2023174945A (ja) ポリペプチド製剤の偽型腫瘍溶解性ウィルス送達
Hopp et al. Atypical B cells up-regulate costimulatory molecules during malaria and secrete antibodies with T follicular helper cell support
Rosigkeit et al. Monitoring translation activity of mRNA-loaded nanoparticles in mice
TW202227478A (zh) 對細胞靶向遞送的藥劑及方法
MXPA05000302A (es) Uso de hmgb1 en el tratamiento de dano de tejido y/o para promover la reparacion de tejido.
CN122070366A (zh) 环状rna组合物和方法
CN107847516A (zh) 用ctla‑4拮抗剂增强免疫应答的方法
US20240158861A1 (en) Methods and compositions for treating cell senescence accumulation related disease
van der Wal et al. The importance of the Atlantic salmon peritoneal cavity B cell response: Local IgM secreting cells are predominant upon Piscirickettsia salmonis infection
Franke et al. Transmembrane protein PERP is a component of tessellate junctions and of other junctional and non-junctional plasma membrane regions in diverse epithelial and epithelium-derived cells
Wu et al. Short-chain fatty acids alleviate vancomycin-caused humoral immunity attenuation in rabies-vaccinated mice by promoting the generation of plasma cells via Akt-mTOR pathway
JP2016535060A (ja) 細胞傷害性t細胞応答の修飾物質
US11357787B2 (en) Method for selecting cells, method for producing nucleic acid, method for producing recombinant cells, method for producing target substance, method for producing pharmaceutical composition, and reagent
AR132064A1 (es) Anticuerpos anti-cldn6 y métodos de uso
CN105968199B (zh) 抗电压门控钾通道1.3胞外环肽段的单克隆抗体及应用
CN104497065A (zh) α-半乳糖神经酰胺新异构体及其用途
Liu et al. Proteasome inhibitors FHND6091 enhance the ability of NK cells to kill tumor cells through multiple mechanisms
JP7452918B2 (ja) マクロファージの製造方法、分化誘導剤、分化誘導キット、マクロファージの分化誘導方法、マクロファージの増殖促進剤、マクロファージの増殖促進キット、マクロファージの増殖方法及びマクロファージ
AR132063A1 (es) Anticuerpos multiespecíficos anti-cldn6 y anti-cd3 y métodos de uso
CN102634478B (zh) 雷公藤红素对内皮前体细胞功能的改善作用
Kardani Investigating extracellular vesicle-mediated interactions between enterococcus faecalis, monocyte-derived macrophages, and endothelial cells
AR132062A1 (es) Anticuerpos multiespecíficos anti-cd3 y métodos de uso
Carty Pulmonary lymphatic remodeling in response to influenza-induced inflammation
Rose Identifying mechanisms of resistance to oncolytic virotherapy in acute leukemia through a genome-wide CRISPR screen